Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Upfront ustekinumab to reduce toxicity from dual immune checkpoint blockade in pleural mesothelioma
NL-OMON61347Phase 2Not yet recruiting
- Sponsor
- Erasmus MC
- Start
- Aug 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ustekinumab in pleural mesothelioma, sponsored by Erasmus MC. Primary endpoint: Incidence of severe immune-related adverse events. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
ustekinumab
03
Conditions
pleural mesothelioma
Beyond the preview
Go deeper on NL-OMON61347.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61347.